Health
Half of Americans not equipped to provide life-saving treatment in a crisis, poll finds
Only half the people in the U.S. feel they could be helpful in an emergency situation, a new poll found.
The Ohio State University Wexner Medical Center surveyed a national sample of 1,005 Americans, finding that only 51% of them knew how to perform hands-only CPR if needed.
In cases of serious bleeding, only 49% said they could assist, and 56% said they would be equipped to help someone who was choking.
The data was collected via phone and email from April 5 to April 7 of this year.
KIDS AS YOUNG AS 4 YEARS OLD CAN BEGIN TO LEARN MEDICAL EMERGENCY TRAINING: NEW REPORT
“The key takeaways from our survey are that patient outcomes would improve if the general public learned some basic life-saving measures in the areas of hands-only CPR, choking rescue and bleeding control,” Nicholas Kman, M.D., emergency medicine physician at Ohio State Wexner Medical Center and clinical professor of emergency medicine at The Ohio State University College of Medicine, told Fox News Digital.
“We can save lives while we wait for first responders to arrive.”
Only half the people in the U.S. feel they could be helpful in an emergency situation, a new poll has found. (iStock)
“For every minute that passes, the chance of survival drops, and if they do survive, there’s less chance of a good neurologic outcome.”
Data shows that 70% to 80% of cardiac arrests occur in the home and 20% happen in a public place, according to Kman.
HELP DESPERATELY NEEDED: AMERICAN HEART ASSOCIATION LAUNCHES ‘NATION OF LIFESAVERS’ PROGRAM
“Outcomes are poor when the arrest is unwitnessed at home,” he told Fox News Digital.
“Just think, the person with the medical emergency could be your loved one in your house. You may have to provide life-saving treatment until first responders arrive.”
Data shows that 70% to 80% of cardiac arrests occur in the home and 20% happen in a public place, a researcher said. (iStock)
Based on the survey findings, Kman advised the public to get trained in life-saving measures — particularly hands-only CPR, choking and serious bleeding.
“Look for training that may be offered through community days at hospitals, schools, libraries, community organizations, religious institutions, volunteer groups, festivals and sporting events,” he suggested.
“We’re responsible for each other.”
Organizations and websites such as the American Red Cross, the American Heart Association and Stop The Bleed may offer these courses for free or low cost, Kman noted.
After learning the skills, it’s important to practice them, the doctor said.
“We would love the public to learn how to do hands-only CPR and practice the skill of doing CPR every six weeks,” Kman said.
Based on the survey findings, researchers advised people to get trained in life-saving measures, particularly hands-only CPR, choking first-aid and serious bleeding assistance. (iStock)
“As with any skill, practice builds confidence. If we don’t practice it, we lose that skill.”
The OSU survey did have some limitations, Kman acknowledged.
“The survey was a convenience sample of a cross-section of Americans,” he told Fox News Digital.
HEART ATTACKS MORE LIKELY DURING PRESIDENTIAL ELECTIONS AND OTHER STRESSFUL TIMES, STUDY SHOWS
“Most demographics were equally represented, but different regions do better at this than others, and their cardiac arrest results and survival reflect that,” he continued.
“States and countries that prioritize training the public have higher survival rates.”
“When you’re trained in these lifesaving skills, you’ll know how to recognize the signs that someone needs help and buy time until the [first] responders can get there,” a doctor said. (iStock)
Dr. Kenneth Perry, an emergency department physician in South Carolina, was not involved in the survey but said he was surprised that more people don’t feel unprepared.
“Even for medical professionals, having a medical emergency occur without preparation can be a very stressful event,” he told Fox News Digital.
“It is very important for people to have basic lifesaving skills.”
“It is very important for people to have basic lifesaving skills.”
The easiest and most helpful skill that people should learn is how to operate an automated external defibrillator (AED). These are located in many public places, such as gyms, malls and even some public walkways, according to Perry.
“These devices are the best way to save a person who is suffering from cardiac arrest,” he said.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“If the person has an abnormal heart rhythm that can be brought back to normal with electricity, this device will save that patient.”
This is a very time-sensitive process, however — it must happen as early as possible, the doctor advised.
“Early defibrillation is directly correlated with the best outcomes for patients who suffer an out-of-hospital cardiac arrest.”
Ultimately, Kwan, said, “we’re responsible for each other.”
“When you’re trained in these lifesaving skills, you’ll know how to recognize the signs that someone needs help and buy time until the responders can get there.”
For more Health articles, visit www.foxnews.com/health.
NEWYou can now listen to Fox News articles!
During a recent episode of her podcast, Gwyneth Paltrow spoke with neuroscientist Dr. Andrew Huberman about retatrutide, a new advancement in GLP-1 (glucagon-like peptide-1) therapies.
In recent years, GLP-1 receptor agonists have become a major focus in discussions around biohacking, longevity and wellness – but they’re not without a multitude of side effects.
Huberman noted that while first-generation weight-loss drugs curbed users’ appetites, they frequently plunged them into massive, rapid caloric deficits.
‘NEXT OZEMPIC’ AIMS TO DELIVER 30% WEIGHT LOSS WITH FEWER SIDE EFFECTS
Without aggressive resistance training, a high percentage of that lost weight came directly from lean muscle. “People would lose a ton of weight, but they would also lose muscle mass,” Huberman told Paltrow.
In clinical trials, retatrutide is administered as a once-weekly subcutaneous injection. (iStock)
That is where retatrutide comes in, he said. Unlike older single- or dual-action medications, retatrutide is a triple agonist.
That means it activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon – three hormones involved in regulating blood sugar, appetite and metabolism.
WEIGHT-LOSS EXPERTS PREDICT 5 MAJOR TREATMENT CHANGES LIKELY TO EMERGE IN 2026
“Retatrutide is a more mild agonist of GLP-1,” said Huberman. “It also increases glucagon and … GIP. So, it hits three different pathways, each a bit more subtly.”
In clinical trials, retatrutide is administered as a once-weekly subcutaneous injection.
Without aggressive resistance training, a high percentage of lost weight can come directly from lean muscle mass, said Andrew Huberman. (iStock)
Because of its balanced, multi-receptor approach, Huberman said the drug has a “lower side effect profile” while still allowing people to lose up to a third of their body weight “across a year or so.”
NEW OZEMPIC-ALTERNATIVE DIABETES PILL BURNS FAT WITHOUT MUSCLE LOSS, STUDY SUGGESTS
Most importantly for fitness and longevity advocates, the doctor pointed out that retatrutide seems to have “some muscle sparing effect.”
Because the drug is still moving through official pipelines, a massive gray market of compounding pharmacies and online peptide suppliers has cropped up to meet the growing demand.
Retatrutide is an investigational molecule that is legally available only to participants in Lilly’s clinical trials, according to Lilly’s website, and the company is currently “evaluating its safety and efficacy” in these clinical studies. (iStock)
Huberman issued a strict warning regarding these unregulated online sources, noting that these options “can say 99% purity, but that 1% means there could be some LPS,” referring to lipopolysaccharides, a type of bacterial toxin.
CLICK HERE FOR MORE HEALTH STORIES
“LPS will cause inflammation,” he cautioned. “One injection isn’t gonna do it, but multiple injections over time, I could see where that could become problematic.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Paltrow echoed the safety concerns, comparing the current “wild-west” peptide craze to the landscape of supplements in the 90s, “where there’s really no third-party testing and it’s kind of word of mouth.”
“Multiple injections over time, I could see where that could become problematic.”
Both agreed that anyone exploring these therapies should avoid unverified online sources and prioritize working with a medical doctor.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Retatrutide is an investigational molecule that is legally available only to participants in Lilly’s clinical trials, according to the manufacturer’s website. The company is currently “evaluating its safety and efficacy.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The drug has not been reviewed or approved by any regulatory agency, and no one should consider taking anything claiming to be retatrutide outside of a Lilly-sponsored clinical trial, experts advise.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial.
Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan (sac-TMT) met its “primary endpoints” of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.
The TroFuse-005 trial is the first global Phase 3 trial to “demonstrate statistically significant improvement” in survival compared to chemotherapy in these patients, according to a Merck press release.
WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN, MAJOR NEW STUDY REVEALS
This was also the first and only antibody-drug conjugate (ADC) to achieve such a result for endometrial cancer patients in this setting, the researchers stated.
An ADC is a targeted cancer therapy that delivers more of the drug to tumor cells while limiting damage to healthy cells.
The investigational drug, sac-TMT, is administered every two weeks via IV infusion. (iStock)
The trial involved 776 patients with endometrial cancer whose disease worsened after receiving both platinum chemotherapy and immunotherapy.
The patients were randomly assigned sac-TMT, administered every two weeks, or a treatment of the physician’s choice, including doxorubin or paclitaxel chemotherapy. The patients were aware of which treatment they were receiving.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Those receiving sac-TMT showed “clinically meaningful improvement” in their disease state compared to the treatment of physician’s choice, the researchers found.
The study also met response rate benchmarks and exhibited similar side effects to earlier studies of the same drug, Merck reported.
NEW BREAST CANCER DRUG WINS FDA APPROVAL AFTER SLASHING PROGRESSION RISK BY NEARLY 40%
The drugmaker did not disclose any statistics on exact survival benefit, response rate, side effect rates or other details, but the researchers aim to present this Phase 3 data at an upcoming medical meeting.
The drug “may be able to address a critical unmet need for certain patients with advanced endometrial cancer,” said the lead researcher (not pictured). (iStock)
Dr. Domenica Lorusso, the study’s global lead investigator and professor of obstetrics and gynecology at Humanitas University and Humanitas San Pio X in Milan, wrote in a press release that these results show sac-TMT “may be able to address a critical unmet need for certain patients with advanced endometrial cancer, one of the only cancers increasing in both incidence and mortality worldwide.”
CLICK HERE FOR MORE HEALTH STORIES
“Despite recent advances, patients whose disease progresses following treatment with platinum and immunotherapy are urgently in need of new options, and these findings show for the first time that a TROP2 ADC may be an effective option in this setting,” she added.
Dr. Brian Slomovitz, co-director of gynecologic oncology at Mount Sinai and an investigator on this trial, reflected on the study findings during an interview with Fox News Digital.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“Unlike many other cancers that we are treating, the number of endometrial cancers and the number of deaths due to endometrial cancers are on the rise,” Slomovitz noted.
“In the United States, the number of deaths due to endometrial cancer has surpassed the number of deaths due to ovarian cancer, [making it] the deadliest of all gynecologic malignancies.”
Endometrial cancer has become “the deadliest of all gynecologic malignancies,” one doctor shared. (iStock)
Despite recent advancements introducing immunotherapy as the standard of care, “better treatment options” for patients with recurrent disease “remains an unmet need,” Slomovitz commented.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“If the full data confirm this announcement, the key questions will be the magnitude of the survival benefit and the toxicity profile — those will define sac-TMT’s role,” he said.
“But an overall survival improvement in recurrent disease is a real, meaningful result for patients and their families, not just a statistical one.”
-
Tennessee3 minutes ago
TN Lottery Powerball, Lotto America winning numbers for May 20, 2026
-
Texas9 minutes agoStorm cleanup continues after Central Texas thunderstorms topple trees, damage roads
-
Utah15 minutes agoUtah professor explains legality of settlement granted to Tennessee man jailed for controversial meme
-
Vermont21 minutes agoEvents in Burlington and beyond for your Memorial Day weekend
-
Virginia27 minutes agoSouthwest, Central Virginia Weather | 11 p.m. – May 20, 2026
-
Wisconsin39 minutes agoCommunity rallies for performance of "A Mother of a Revolution"
-
West Virginia45 minutes agoWest Virginia DMV says people will not have to retake driver’s tests
-
Wyoming51 minutes agoFormer Wyoming Minister ‘Unequivocally Denies’ Claims Of Sex Abuse Against Boys
